Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Current Market share versus March according to PharmaTrac: Eli Lilly - down to 56 per cent from 61 per cent in March (Mounjaro - tirezepatide) NovoNordisk - stable at 25 per cent (Ozempic/Wegovy - semaglutide) Cipla - down to 10 per cent from 12 per cent in March (Yurpeak- tirezepatide) Torrent Pharma - 3 per cent (Sembolic and Semalix - oral tablets and injections) Current market estimates for GLP-1 drugs stands at Rs 1,600 crore, expected to increase Mounjaro starts at Rs 13,000 per month Ozempic starts at Rs 5,500 per month Generic Semaglutide starts as low as 1300 per month Semaglutide is a an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
Meijer pharmacies offering GLP-1 weight loss medications at lower prices with savings programs FOX 2 - A new program by Meijer pharmacies is providing more access to GLP-1 weight loss medication in Michigan
This shift can impact the amount of food purchased, the types of foods purchased, and the amount of food wasted. Participants were then asked to rate the likelihood that GLP-1 drugs will impact economic outcomes (e.g., profitability) of different food system players, from 1=very unlikely to 7=very likely
Patients must enroll in the iPLEDGE program to receive their medication from the pharmacy
